Reasons for initiation of mTOR inhibitor treatment were symptomatic cardiac rhabdomyomas and arrhythmia in 6 (35.3%), SEGA in 5 (29.4%), the combination of cardiac rhabdomyoma and SEGA in 1 (5.9%), refractory epilepsy in 4 cases (23.5%) and congenital focal lymphedema in 1 case (5.9%) (Table 1, Fig. 1). Here, MTOR is linked to cardiac arrhythmia.